Neural biomarker of functional disability in major depressive disorder: A structural neuroimaging study

2021 ◽  
pp. 110337
Author(s):  
Rubai Zhou ◽  
Jun Chen ◽  
Guoqing Zhao ◽  
Zuowei Wang ◽  
Daihui Peng ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Functional Disability ◽  
Major Depressive ◽  
Structural Neuroimaging ◽  
Neuroimaging Study

scholarly journals Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Cynthia HY Fu ◽  
Sergi G Costafreda ◽  
Anjali Sankar ◽  
Tracey M Adams ◽  
Mark M Rasenick ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Structural Neuroimaging

scholarly journals Associations between increased circulating endothelial progenitor cell levels and anxiety/depressive severity, cognitive deficit and function disability among patients with major depressive disorder

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ying-Jay Liou ◽  
Mu-Hong Chen ◽  
Ju-Wei Hsu ◽  
Kai-Lin Huang ◽  
Po-Hsun Huang ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cognitive Deficit ◽  
Functional Disability ◽  
Rating Scale ◽  
Short Form ◽  
Digit Symbol Substitution Test ◽  
Endothelial Progenitor ◽  
Major Depressive ◽  
And Function

AbstractThe association of major depressive disorder (MDD) with cardiovascular diseases (CVDs) through endothelial dysfunction is bidirectional. Circulating endothelial progenitor cells (cEPCs), essential for endothelial repair and function, are associated with risks of various CVDs. Here, the relationship of cEPC counts with MDD and the related clinical presentations were investigated in 50 patients with MDD and 46 healthy controls. In patients with MDD, a battery of clinical domains was analysed: depressed mood with Hamilton Depression Rating Scale (HAMD) and Montgomery–Åsberg Depression Rating Scale (MADRS), anxiety with Hamilton Anxiety Rating Scale (HAMA), cognitive dysfunction and deficit with Digit Symbol Substitution Test (DSST) and Perceived Deficits Questionnaire-Depression (PDQ-D), somatic symptoms with Depressive and Somatic Symptom Scale (DSSS), quality of life with 12-Item Short Form Health Survey (SF-12) and functional disability with Sheehan Disability Scale (SDS). Immature and mature cEPC counts were measured through flow cytometry. Increased mature and immature cEPC counts were significantly associated with higher anxiety after controlling the confounding effect of systolic blood pressure, and potentially associated with more severe depressive symptoms, worse cognitive performance and increased cognitive deficit, higher social disability, and worse mental health outcomes. Thus, cEPCs might have pleiotropic effects on MDD-associated symptoms and psychosocial outcomes.

scholarly journals Cognitive impairment in major depressive disorder

CNS Spectrums ◽  
2018 ◽  
Vol 24 (1) ◽  
pp. 22-29 ◽  
Author(s):  
Zihang Pan ◽  
Caroline Park ◽  
Elisa Brietzke ◽  
Hannah Zuckerman ◽  
Carola Rong ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Cognitive Dysfunction ◽  
Cognitive Deficits ◽  
Functional Disability ◽  
Testable Hypothesis ◽  
Major Depressive ◽  
Cognitive Domains ◽  
Patient Reported ◽  
Neurobiological Substrates

Cognitive dysfunction is a symptomatic domain identified across many mental disorders. Cognitive deficits in individuals with major depressive disorder (MDD) contribute significantly to occupational and functional disability. Notably, cognitive subdomains such as learning and memory, executive functioning, processing speed, and attention and concentration are significantly impaired during, and between, episodes in individuals with MDD. Most antidepressants have not been developed and/or evaluated for their ability to directly and independently ameliorate cognitive deficits. Multiple interacting neurobiological mechanisms (eg, neuroinflammation) are implicated as subserving cognitive deficits in MDD. A testable hypothesis, with preliminary support, posits that improving performance across cognitive domains in individuals with MDD may improve psychosocial function, workplace function, quality of life, and other patient-reported outcomes, independent of effects on core mood symptoms. Herein we aim to (1) provide a rationale for prioritizing cognitive deficits as a therapeutic target, (2) briefly discuss the neurobiological substrates subserving cognitive dysfunction, and (3) provide an update on current and future treatment avenues.

Sex differences in the mediators of functional disability in Major Depressive Disorder

2018 ◽  
Vol 96 ◽  
pp. 108-114 ◽  
Author(s):  
Nicole E. Carmona ◽  
Mehala Subramaniapillai ◽  
Rodrigo B. Mansur ◽  
Danielle S. Cha ◽  
Yena Lee ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Sex Differences ◽  
Depressive Disorder ◽  
Functional Disability ◽  
Major Depressive

scholarly journals DNA methylation signatures of C-reactive protein associations with structural neuroimaging measures and major depressive disorder

2020 ◽  
Author(s):  
Claire Green ◽  
Xueyi Shen ◽  
Anna J. Stevenson ◽  
Eleanor L.S. Conole ◽  
Mathew A. Harris ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Brain Structure ◽  
Somatic Symptoms ◽  
Depression Symptoms ◽  
C Reactive Protein ◽  
Major Depressive ◽  
Structural Neuroimaging ◽  
Reactive Protein ◽  
Serum Crp

Background: Inflammatory processes are implicated in the aetiology of Major Depressive Disorder (MDD); however, the relationship between peripheral inflammation, brain structure and depression remains unclear. This study investigates associations between depression, structural neuroimaging measures and two measures of inflammation: serum-based C-reactive protein (CRP) and a methylation-based score for CRP (DNAm CRP) in a large community-based sample. Methods: Serum CRP and DNAm CRP were assessed for participants in Generation Scotland (nMDD cases= 240, nControls= 558) alongside structural brain scans (T1 and diffusion MRI). Linear regression was used to investigate associations between (i) both CRP measures and depressive symptoms, (ii) both CRP measures and structural imaging variables and (iii) inflammation x MDD interaction effects (for both CRP measures) with imaging measures. Results: Increased serum CRP was significantly associated with overall MDD symptom severity and specifically with somatic symptoms- general interest (β= 0.145, pFDR = 6x10-4) and energy levels (β= 0.101, pFDR = 0.027) and also reduced entorhinal cortex thickness (β= -0.095, pFDR = 0.037). DNAm CRP was significantly associated with reduced global grey matter/cortical volume and reduced integrity of 16 white matter tracts and showed larger effect sizes (βaverage= -0.15) compared to serum CRP across all measures (βaverage = 0.01). Conclusions: Acute measures of CRP were related to current depression symptoms, specifically somatic symptoms, whereas methylation signatures of inflammation demonstrated greater differences in global and regional brain structure. This study highlights the utility of combining serological and methylation markers to study chronic inflammation effects on the brain in psychiatric disorders.

scholarly journals Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression

2020 ◽  
Vol 23 (9) ◽  
pp. 571-577
Author(s):  
Gernot Fugger ◽  
Markus Dold ◽  
Lucie Bartova ◽  
Marleen M M Mitschek ◽  
Daniel Souery ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Functional Disability ◽  
Treatment Guidelines ◽  
Antidepressant Treatment ◽  
Clinical Information ◽  
Binary Logistic Regression ◽  
Major Depressive ◽  
Caucasian Origin ◽  
Male Patients

Abstract Background The present multicenter study aimed at defining the clinical profile of patients with major depressive disorder (MDD) and comorbid migraine. Methods Demographic and clinical information for 1410 MDD patients with vs without concurrent migraine were compared by descriptive statistics, analyses of covariance, and binary logistic regression analyses. Results The point prevalence rate for comorbid migraine was 13.5% for female and 6.2% for male patients. MDD + migraine patients were significantly younger, heavier, more likely female, of non-Caucasian origin, outpatient, and suffering from asthma. The presence of MDD + migraine resulted in a significantly higher functional disability. First-line antidepressant treatment strategy revealed a trend towards agomelatine. Second-generation antipsychotics were significantly less often administered for augmentation treatment in migraineurs. Overall, MDD + migraine patients tended to respond worse to their pharmacotherapy. Conclusion Treatment guidelines for comorbid depression and migraine are warranted to ensure optimal efficacy and avoid possible pitfalls in psychopharmacotherapy, including serotonin syndrome.

NATURALISTIC COURSE OF MAJOR DEPRESSIVE DISORDER PREDICTED BY CLINICAL AND STRUCTURAL NEUROIMAGING DATA: A 5-YEAR FOLLOW-UP

2016 ◽  
Vol 33 (11) ◽  
pp. 1055-1064 ◽  
Author(s):  
Maria Serra-Blasco ◽  
Javier de Diego-Adeliño ◽  
Yolanda Vives-Gilabert ◽  
Joan Trujols ◽  
Dolors Puigdemont ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Structural Neuroimaging ◽  
Neuroimaging Data
Sign in / Sign up

Export Citation Format

Share Document